MANNKIND CORPORATION

Analyst Reco. MannKind Corporation

Equities

MNKD

US56400P7069

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
4.26 ^USD	+0.71%		+3.65%	+17.03%

12:05pm	MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	CI
Apr. 29	MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	Nov. 14	MT
Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality	23-10-10	MT
HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating	23-08-14	MT
HC Wainwright Adjusts Price Target on MannKind to $7 From $6, Keeps Buy Rating	23-02-27	MT
SVB Securities Adjusts Price Target on MannKind to $6 From $5, Maintains Outperform Rating	22-11-09	MT
HC Wainwright Trims MannKind's Price Target to $6 From $6.50, Maintains Buy Rating	22-02-28	MT
MANNKIND : Initiated at Sector Perform by RBC, Price Target Set at $5/Share	21-05-14	MT
MANNKIND : SVB Leerink Adjusts Price Target on MannKind to $5 From $3, Maintains Outperform Rating	21-03-05	MT
MANNKIND : BTIG Research Adjusts MannKind PT to $8 From $4, Maintains Buy Rating	21-02-24	MT
MANNKIND : Oppenheimer Adjusts MannKind PT to $7 From $3, Maintains Outperform Rating	21-02-17	MT
MANNKIND : Oppenheimer Adjusts MannKind PT to $3 From $2.50, Maintains Outperform Rating	20-11-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer